Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line FOLFIRI plus panitumumab after FOLFOX plus panitumumab in RAS/BRAF wild-type metastatic colorectal cancer
jRCTs041180113Phase 2Completed
- Sponsor
- Takeda
- Start
- Aug 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC), sponsored by Takeda. Primary endpoint: 6-month progression-free survival rate. Started Aug 2017; status: completed.
02
Drugs
panitumumabirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs041180113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180113.